Haleos Labs Limited Q1 FY27 Results (NSE: HALEOSLABS)

5 Aug 2026 · Analysis by Alpha Inflection

Signal: Revenue declined

The read

The main inflection is sequential margin recovery: consolidated EBITDA margin rose to 13.1% from 5.54% in Q4FY26, but revenue still fell 11.59% YoY to ₹7294.23 lakh and margin remained 109bps below Q1FY26; the subsidiary loss and higher raw-material intensity keep the recovery unproven.

P&L walk

Consolidated revenue declined to ₹7294.23 lakh, -11.59% YoY and -2.92% QoQ; EBITDA margin was 13.1%, down 109bps YoY but up 756bps QoQ, while PAT increased 43.82% YoY as the prior-year comparison was depressed.

Segments

The group is single-segment API/intermediate manufacturing, but the subsidiary dragged consolidated earnings with ₹1025.24 lakh revenue and a ₹201.58 lakh net loss; standalone PAT was ₹323.78 lakh versus consolidated PAT of ₹264.66 lakh.

Key positives

• Consolidated EBITDA margin recovered to 13.1% from 5.54% QoQ, a 756bps sequential improvement, after the Q4FY26 trough.
• Consolidated PAT rose 43.82% YoY to ₹264.66 lakh despite revenue declining 11.59%, with other income of only ₹46.33 lakh and clean earnings quality.
• Standalone EBITDA margin of 14.9% exceeded the consolidated 13.1%, indicating the parent business remained more profitable than the group.

Key concerns

• Revenue declined 11.59% YoY to ₹7294.23 lakh and 2.92% QoQ, extending the weak top-line trajectory after Q4FY26 revenue of ₹7513.91 lakh.
• Raw-material consumption increased to 55.03% of consolidated revenue from 33.61% YoY, while the gross-margin improvement was helped by a ₹1368.21 lakh inventory-change credit; the underlying cost signal requires confirmation.
• The subsidiary reported a ₹201.58 lakh net loss on ₹1025.24 lakh revenue, reducing consolidated PAT to ₹264.66 lakh from standalone PAT of ₹323.78 lakh.

View original filing

Research and educational content only. Not investment advice.